Several possible studies
Story checked
Potential new TB vaccines could save millions of lives: Gavi (opens in a new tab)
medicalxpress.com · 2026-09-14
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Potential new TB vaccines could save millions of lives: Gavi
medicalxpress.com · 2026-09-14
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedNew tuberculosis vaccines expected to become available from 2029 could save more than 7 million lives over a decade, Gavi said.View evidenceHide evidence
As statedmore than 7 million lives over a decade
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 4Not checkedGavi said the first promising candidate vaccines are expected to secure regulatory approval by the end of the decade, and a fresh Gavi analysis found they could avert up to 7.3 million deaths from 2030 through 2050.View evidenceHide evidence
As statedup to 7.3 million deaths from 2030 through 2050
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 4Not checkedThe analysis also said the new vaccines could unlock up to $135 billion in economic benefits across low- and middle-income countries by midcentury.View evidenceHide evidence
As statedup to $135 billion
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 4Not checkedGavi warned that inadequate global and domestic financing, uncertain demand, and resulting manufacturer capacity risks could slow rollout after licenses are secured.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Expanding the Frontiers of Tuberculosis Prevention: Moving from Targeted Preventive Therapy to Integrated Public Health Strategies.
Tropical Medicine and Infectious Disease · 2026 · PubMed
Mortality Rate in Pakistan - among Low and Middle-Income Countries
Mortality Rates in Middle and Low-Income Countries · 2022 · Crossref
Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access.
The Lancet. Microbe · 2027 · PubMed, Europe PMC
Temporal shifts in adaptive immunity drive HIV-associated cryptococcal IRIS: mechanisms, models, and therapeutic opportunities.
NeuroImmune Pharmacology and Therapeutics · 2026 · PubMed
Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study
Vaccine: X · 2023 · Crossref
And 10 more candidates considered.